drugset / Trial / NCT03712787
An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
Non-randomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in participants with early AD.
Timeline
- Start
- 2019-03-22
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
Outcome
Outcome not reported
Stopped: “Discontinued because of lack of efficacy in the parent study (Study M15-566; NCT02880956).”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tilavonemab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Tilavonemab | Monoclonal antibody | 2000 mg | Intravenous |